CHMP recommends Perjeta (Genentech/Roche) for HER2+ Breast Cancer

The CHMP has given a positive opinion for the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel in patients with HER2-positive metastatic or locally recurrent unresectable Breast Cancer (mBC). The recommendation supports an indication for people with this specific type of cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease. The CHMP opinion is based on positive overall survival and progression-free survival data from the Phase III CLEOPATRA study. Updated overall survival results recently reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium showed the risk of death was reduced by 34 percent for people who received the Perjeta combination.